In New Zealand, silicosis is managed by occupational medicines. Silicosis is an incurable, progressive fibrotic lung disease caused by inhalation of respirable crystalline silica dust at workplaces such as stone-cutting, quarrying, mining, sandblasting, foundry work, construction, and (increasingly) artificial-stone benchtop fabrication. Global Burden of Disease 2019 estimated approximately 23 million people exposed to occupational silica and over 12,000 silicosis deaths per year, with rapidly rising cases from engineered-stone (artificial quartz) workers in Australia, Europe, the United States, India, and Israel.
Silicosis (ICD-10: J62.8) is an irreversible occupational interstitial lung disease caused by inhalation and pulmonary retention of respirable crystalline silica particles, predominantly α-quartz, cristobalite, or tridymite. Particles smaller than 5 microns reach the alveoli, where they are taken up by alveolar macrophages. Macrophages release inflammatory mediators (IL-1β, TNF-α, TGF-β), recruit more inflammatory cells, and ultimately die from oxidative damage, releasing the silica to be re-ingested in a self-perpetuating cycle. The result is characteristic silicotic nodules — concentric whorls of hyalinised collagen surrounding macrophage-engulfed silica — concentrated in the upper and posterior lung zones, with progressive nodular fibrosis.
The key symptoms of Silicosis are: Progressive exertional breathlessness developing over months to years, often noticed first on stairs or hills., Persistent dry cough, sometimes with scant mucoid sputum, that may persist for years before formal diagnosis., Reduced exercise tolerance with disproportion between symptoms and chest examination in early disease., Fatigue, weight loss, and reduced appetite particularly in accelerated and acute forms., Pleuritic chest pain, intercostal aching, or a sensation of chest tightness in advanced disease., Haemoptysis raising concern for tuberculosis, lung cancer, or progressive massive fibrosis cavitation., Recurrent chest infections including productive cough and prolonged recovery in chronic bronchitic forms..
Diagnosis requires three elements: a credible history of significant respirable crystalline silica exposure (occupation, duration, dust controls, respiratory protection), characteristic imaging changes, and exclusion of mimicking diseases. A detailed occupational history covers all relevant jobs, tasks performed, dust controls used, respirator type and fit, hobbies (stone-working, ceramics), and time since last exposure. The International Labour Organization (ILO) classification of pneumoconiosis radiographs grades small rounded opacities by size (p, q, r) and profusion (categories 0/0 to 3/+) using standard reference films. High-resolution CT of the chest is far more sensitive and shows centrilobular and perilymphatic small nodules, predominantly upper-lobe and posterior, with subpleural pseudoplaques, mediastinal lymphadenopathy (sometimes with eggshell calcification), and conglomerate masses in PMF. Pulmonary function testing typically shows restrictive or mixed restrictive-obstructive impairment; in advanced disease, gas transfer (DLco) is reduced. Bronchoalveolar lavage may show silica particles under polarised microscopy. Surgical or transbronchial lung biopsy is occasionally needed to exclude other granulomatous diseases. Annual tuberculosis screening with IGRA, sputum acid-fast bacilli, and chest imaging is essential. Connective tissue disease screening (rheumatoid factor, anti-CCP, ANA, ANCA, anti-Scl-70) is recommended. Lung cancer surveillance with low-dose CT is considered in selected high-risk patients. Differential diagnosis includes sarcoidosis (sharply demarcated upper lobe nodules with hilar lymphadenopathy), hypersensitivity pneumonitis, tuberculosis, fungal lung disease, lung cancer, beryllium disease, and coal workers' pneumoconiosis.
Outcomes depend on disease type, stage, ongoing exposure, smoking, tuberculosis, and access to care. Chronic simple silicosis without progression has slow decline and may be compatible with near-normal life expectancy if exposure ceases and smoking stops. Progressive massive fibrosis carries substantially worse prognosis with rising dyspnoea, cor pulmonale, and respiratory failure; 5-year survival is 50-70% in established PMF. Accelerated silicosis (especially engineered-stone) progresses rapidly with respiratory failure within 5-10 years in many cases. Acute silicoproteinosis has mortality of 70-100% within months to a few years without lung transplantation. Silicotuberculosis substantially raises mortality (3-fold) but is treatable. Lung cancer risk is approximately doubled in non-smoking silicosis patients and synergistically amplified by smoking. End-stage disease may be salvaged by lung transplantation with 5-year survival around 50-60%, comparable to transplantation for idiopathic pulmonary fibrosis. Disability and quality-of-life impairment are profound in advanced disease.
A pulmonologist or occupational medicine physician confirms the diagnosis, classifies disease severity, screens for tuberculosis and autoimmune disease, manages complications, and coordinates compensation and disability claims. Early specialist involvement is critical because exposure cessation is the most powerful intervention.
Find specialists →Silicosis does not reverse. Exposure cessation may slow progression. Symptoms generally progress over years. Pulmonary rehabilitation produces measurable improvements in exercise capacity within 8-12 weeks. Tuberculosis is treated over 6 months with cure rates >90%. Lung transplantation requires lifelong follow-up.
Encourage moderate aerobic exercise (walking, swimming, cycling) for at least 30 minutes 5 days per week within tolerance. Supervised pulmonary rehabilitation is recommended for patients with significant breathlessness. Pace activity, use bronchodilators before exercise if needed, and use supplemental oxygen during activity if prescribed.
Choose a centre with an occupational lung disease clinic, ILO-certified radiograph reading, access to high-resolution CT, full pulmonary function testing, TB clinic links, and lung transplant referral pathways. Familiarity with workers' compensation processes is important.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in New Zealand.
Apply as specialist →Specialists who treat Silicosis. Get expert guidance and personalized care.